Citizens JMP raised the firm’s price target on Rezolute (RZLT) to $17 from $9 and keeps an Outperform rating on the shares. Rezolute remains on track to report top-line data in December from the Phase 3 sunRIZE study evaluating ersodetug in congenital hyperinsulinism, the analyst tells investors in a research note. Citizens remains confident in the potential for positive results driven by compelling efficacy and safety/tolerability demonstrated in the Phase 2b study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Promising Prospects for Rezolute: Buy Rating Backed by Innovative Lead Candidate and Favorable Market Conditions
- 3 ‘Strong Buy’ Small-Cap Stocks Set to Surge, According to Analysts
- 3 Must-See Stocks with Strong-Buy Ratings and a Perfect 10 Score
- Rezolute price target raised to $20 from $15 at Maxim
- Rezolute’s Promising Progress and Financial Strength Justify Buy Rating